Clinical Trial Update: A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) [Phase 3]

View source ↗

Summary

A global Phase 3 trial evaluating midostaurin plus chemotherapy in newly diagnosed FLT3-mutation negative AML completed with posted results in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Midostaurin (midostaurin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myeloid Leukemia (AML) | Phase 3 | Status: COMPLETED | Results posted: 2023-06-18